Evidence map›Paper›PMID 35662493›Full record

ReviewPET clinics2022

Molecular Imaging Assessment of Androgen Deprivation Therapy in Prostate Cancer.

Hossein Jadvar, Patrick M Colletti

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in PET clinics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hossein JadvarDivision of Nuclear Medicine, Department of Radiology, USC Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: jadvar@med.usc.edu.
Patrick M CollettiDivision of Nuclear Medicine, Department of Radiology, USC Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
University of Southern California · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Saul Priceman · 1985 to 2026
$181.4M
FDG PET-CT in Metastatic Prostate CancerR01CA111613 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JADVAR, HOSSEIN · 2005 to 2010
$2.5M
Pilot Human Studies of FMAU PET in Prostate CancerR21EB017568 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JADVAR, HOSSEIN · 2015 to 2016
$433k
[F18]FMAU in Prostate CancerR21CA142426 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JADVAR, HOSSEIN · 2009 to 2010
$393k
NCI NIH HHS P30 CA014089NCI NIH HHS R01 CA111613NCI NIH HHS R21 CA142426NIBIB NIH HHS R21 EB017568
6 · The paper itself

Abstract

Hormonal therapy has long been recognized as a mainstay treatment for prostate cancer. New generation imaging agents have provided unprecedented opportunities at all phases along the natural history of prostate cancer. We review the literature on the effect of androgens and androgen deprivation therapy on prostate tumor at its various biological phases using the new generation molecular imaging agents in conjunction with positron emission tomography.

Indexed as

Prostatic NeoplasmsAndrogen AntagonistsAndrogensHumansMaleMolecular ImagingPositron-Emission TomographyPositron Emission Tomography Computed TomographyAndrogen AntagonistsAndrogensAndrogenCholineFDGFluciclovineHormoneImagingProstatePSMA

Identifiers

PMID35662493
PMCPMC9232915
OpenAlexW4281935920

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.